Where is Mediwatch located?

Mediwatch is headquartered in Rugby, United Kingdom.

How many employees does Mediwatch have?

As of May 31, 2026, the latest employee count at Mediwatch is 12.

Is Mediwatch a funded company?

Mediwatch is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Mediwatch rank among its competitors?

Mediwatch ranks 32nd amongst 43 active competitors, of which 13 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Nanostics, which secured an undisclosed amount in Apr, 2024.

Who are the top competitors of Mediwatch?

Mediwatch's top competitors include Artera, MDxHealth and Opko Health. Among them, Nanostics secured the most recent funding round in April, 2024.

Mediwatch - 2026 Company Profile, Competitors & Financials

Company Details

Mediwatch develops and markets a range of urodynamics, ultrasound and biochemistry systems used in the diagnosis of urological disorders and the detection of early prostate cancer. It also sells disposables to work with its products. The company's products include urodynamics systems, disposables, bladder scanners, uroflowmeters, testing, pelvic floor biofeedback, and anorectal manometry systems. It sells its products in the UK, US, and Internationally. As of January 27, 2014, Mediwatch plc operates as a subsidiary of Laborie Medical Technologies Europe Limited.

Website: mediwatch.com
Social
Email ID: *****@laborie.com

Key Metrics

Founded Year

1996

Location

Rugby, United Kingdom

Stage

Acquired

Ranked

32^nd among 43 active competitors

Employee Count

12 as on May 31, 2026

Similar Companies

Artera & 55 more

Exit Details

Acquired by Laborie Medical (Nov 18, 2013)

View Mediwatch's full profile

Mediwatch is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MEDIWATCH LIMITED CIN: 3971079 , Germany, Active	Apr 11, 2000	-	51 (As on Oct 31, 2013)

Mediwatch got acquired by Laborie Medical on Nov 18, 2013.

Click here to take a look at Mediwatch's acquisition in detail

Mediwatch is a funded company.

Mediwatch's employee count trend

Mediwatch has 12 employees as of May 26. Here is Mediwatch's employee count trend over the years:

Uncover Mediwatch's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mediwatch include Artera, MDxHealth and Opko Health. Here is the list of Top 10 competitors of Mediwatch, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, EDBI & 23 others	68/100
2nd	MDxHealth 2003, Irvine (United States), Public	Provider of epigenetic tests for personalized cancer assessment and treatment	-	Life Sciences Partners, Andera Partners & 13 others	60/100
3rd	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Gates, Oracle & 1 others	58/100
4th	ProteoMediX 2010, Schlieren (Switzerland), Acquired	Developer of next-generation blood test for prostate cancer	$17.6M	Venture Kick, Altos Ventures Management & 3 others	55/100
5th	GenomeDx Biosciences 2008, San Diego (United States), Series C	Genomic tests for urologic cancers	$69.7M	Merck Global Health Innovation Fund, Calibrium ... & 6 others	46/100
6th	Immunis.AI 2012, Royal Oak (United States), Series C	Provider of platform for the detection of cancer	$40M	Savitr Capital	44/100
7th	Eigen 1973, Grass Valley (United States), Funding Raised	Developer of centralised lab based imaging tools	-	NIH, HHS	41/100
8th	Prostatype Genomics 2007, Solna (Sweden), Unfunded	Developer of a diagnostic test for the detection of prostate cancer	-	-	41/100
9th	Minomic 2000, Sydney (Australia), Series A	Non-invasive blood tests for cancer	$8.13M	ARC, M.H. Carnegie & Co & 1 others	41/100
10th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	40/100
32nd	Mediwatch 1996, Rugby (United Kingdom), Acquired	Portfolio of diagnostic products for urological diseases	-	-	26/100